Please use this identifier to cite or link to this item:
|Title:||Hemostatic and thrombotic markers in patients with hemoglobin E/β-thalassemia disease|
Faculty of Medicine, Ramathibodi Hospital, Mahidol University
|Citation:||American Journal of Hematology. Vol.82, No.11 (2007), 1001-1004|
|Abstract:||Increased frequency of thrombosis has been observed in patients with hemoglobin E/β-thalassemia (Hb E/β-thal) disease, particularly those who have previously been splenectomized. We compared various hemostatic and thrombotic markers in blood from 15 Hb E/β-thal patients who were not splenectomized (NS), 15 who had been splenectomized (S), and 15 normal controls (NC). Levels of plasma thrombin-antithrombin, β2 thromboglobulin, C-reactive protein, tissue plasminogen activator antigen were significantly higher in the S group than in either the NS or the NC groups, and levels of prothrombin fragment 1.2 were significantly higher in the S than in the NC group. Levels of plasminogen activator inhibitor-1 antigen were significantly higher in the S than in the NS group. Levels of protein C, protein S, antithrombin, and fibrinogen were significantly lower in the S and NS groups than in the NC group. Plasma lipoprotein(a) levels in the S and NS groups were not statistically different from NC. Our findings indicated that there is evidence of chronic low-grade coagulation and platelet activation, chronic low-grade inflammation, endothelial cell injury, impaired fibrinolysis, and decreased naturally occurring anticoagulants in splenectomized Hb E/β-thal patients. These changes may account for the increased risk of thrombosis in these patients. © 2007 Wiley-Liss, Inc.|
|Appears in Collections:||Scopus 2006-2010|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.